Inhibiting cellular proliferation by expressing yin yang-1

Details Inhibiting cellular proliferation by expressing yin yang-1 Inhibiting cellular proliferation by expressing yin yang-1

2002-05-21

2009-06-02

Kelly, Robert M (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S093100, C435S320100, C435S325000, C623S001100

Reexamination Certificate

active

07541343

ABSTRACT:
The present invention provides a method of preventing or reducing cellular proliferation. The method involves administering to cells a composition which increases the level of YY1 protein, in particular YY1 mRNA, in the cells.

REFERENCES:
patent: 5856121 (1999-01-01), Gorski et al.
patent: 98/02885 (1998-02-01), None
patent: WO91/00047 (1991-01-01), None
patent: WO94/26914 (1994-11-01), None
patent: WO94/28152 (1994-11-01), None
patent: WO95/02697 (1995-01-01), None
patent: WO95-03400 (1995-02-01), None
patent: WO95/27071 (1995-10-01), None
patent: WO96/03508 (1996-02-01), None
patent: WO96/09400 (1996-03-01), None
patent: WO96/10088 (1996-04-01), None
patent: WO96/22378 (1996-07-01), None
patent: WO96/25506 (1996-08-01), None
patent: WO96/33623 (1996-10-01), None
patent: WO97/12622 (1997-04-01), None
patent: WO97/17457 (1997-05-01), None
patent: WO98/05754 (1998-02-01), None
patent: WO98/05759 (1998-02-01), None
patent: WO98/05854 (1998-02-01), None
patent: WO98/18815 (1998-05-01), None
patent: WO98/30707 (1998-07-01), None
Meier, et al. (1994) Molecular and Cellular Biology, 14(1): 128-37.
Zambrano, et al. (1997) Biochem. J., 328: 293-300.
Thomas, et al. (1999) Gene, 236, 197-208, pp. 197-198.
Shi, et al. (1997) Biochimica et Biophysica Acta, 1332: F49-F66.
Verma et al. (1997) Nature, vol. 389, p. 239.
Pfeifer and Verma (2001) Annu. Rev. Genomics. Hum. Genet. 2:177-211.
Johnson-Saliba et al. (2001) Curr. Drug. Targets 2:371-99.
Shoji et al. (2004) Current Pharmaceutical Design 10 :785-796.
Lundberg, et al (1999) Experimental Gerontology, 34: 549-57.
Newby, et al. (2000) Journal of Pathology, 190: 300-09.
Hedin, et al. (1988) Journal of Cell Biology, 107: 307-19.
Ace, et al, “Construction and Characterization of a Herpes Simplex Virus Type 1 Mutant Unable to Transinduce Immediate-Early Gene Expression”,J. Virol. 63(5):2260-2269 (May 1989).
Bender, et al., “Evidence That the Packaging Signal of Moloney Murine Leukemia Virus Extends into the Gag Region”,J. Virol. 61(5):1639-1646 (May 1987).
Blomer, et al. “Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector”J. Virol. 71(9):6641-6649 (Sep. 1997).
Chou, and Roizman, The γ134.5 Gene Herpes Simplex Virus 1 Precludes Neuroblastoma Cells from Triggering Total Shutoff of Protein Synthesis Characteristic of Programmed Cell Death in Neural Cells,PNAS89:3266-3270 (Apr. 1992).
Chou, et al. “Differential Response of Human Cells to Deletions and Stop Condons in the γl34.5 Gene of Herpes Simplex Virus”J. Virol. 68(12):8304-8311 (1994).
Coffin, et al., “Retroviruses”HE Varmus, Cold Spring Harbour Laboratory Press Eds.: J.M. Coffin, SM Hughes, pp. 758-763.
Coffin, et al., “Herpes Simplex Virus-Based Vectors” DS (ed). Genetic Manipulation of the Nervous System, Academic Press: London, pp. 99-114, (1996).
Cosset, et al. “High-Titer Packaging Cells Producing Recombinant Retroviruses Resistant to Human Serum”J. Virol. 69(12):7430-7436 (1995).
Cotton, et al. “Chicken Adenovirus (CELO Virus) Particles Augment Receptor-Mediated DNA Delivery to Mammalian Cells and Yield Exceptional Levels of Stable Transformants”J. Virol. 67(7):3777-3785 (1993).
Dedieu, et al., “Vectors for Gene Therapy of Cardiovascular Disease”,Curr Cardiol Rep. 2(1):39-47 (Jan. 2000).
Fisher, et al., “Recombinant Adenovirus Deleted of all Viral Genes for Gene Therapy of Cystic Fibrosis”Virology217:11-22 (1996).
Gorziglia, et al., “Elmination of Both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy”J. Virol. 70(6):4173-4178 (1996).
Gosh-Choudhury, et al., “Human Adenovirus Cloning Vectors Based on Infectious Bacterial Plasmides”Gene50:161-171 (1986).
Hiltunen, et al. Insights into the Molecular Pathogenesis of Atherosclerosis and Therapeutic Strategies Using Gene Transfer,Vasc Med. 5:41-48 (2000).
Kim, et al., “Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1” J. Virol. 72(1):811-816 (1998).
Fallaux, et al., “Characterization of 911:A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors”Hum. Gen. Ther. 7:215-222 (Jan. 1996).
Krougliak, et al., “Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants”Hum. Gen. Ther. 6:1575-1586 (1995).
Laitinen, et al., “Vascular Gene Transfer for the Treatment of Restenosis and Atherosclerosis”Curr Opin Lipidol9(5):465-469 (Oct. 1998).
Lieber, et al., “Recombinant Adenoviruses with Large Deletions Generated by Cred-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors in Vitro and In Vivo”J Virol. 70(12):8944-8960 (Dec. 1996).
Levrero, et al. “Defective and Nondefective Adenovirus Vectors for Expressing Foreign Genes In Vitro and In Vivo”Gene101:195-202 (1991).
MacLean, et al. “Herpes Simplex Virus Type 1 Deletion Variants 1714 and 1716 Pinpoint Neurovirulence-Related Sequences in Glasgow Strain 17+Between Immediate Early Gene 1 and the ‘a’Sequence”J. Gen. Virol. 72:632-639 (1991).
O'Brien, et al. “Gene Therapy for Atherosclerotic Cardiovascular Disease: A Time for Optimism and Caution”Mayo Clinic Proc75(8):831-834 (Aug. 2000).
Pear, et al. “Production of High-Titer Helper Free Retroviruses by Transient Transfection”PNAS90:8392-8396 (Sep. 1993).
Ribault, et al., “Chimeric Smooth Muscle-Specific Enhancer/Promoters”Circ. Res. 88:468-475, (2001).
Rice and Knipe, “Genetic Evidence for Two Distinct Transactivation Functions of the Herpes Simplex Virus α Protein ICP27”J. Virol. 64(4):1704-1715 (1990).
Smith, et al., “Evidence That Herpes Simplex Virus Immediate Early Protein ICP27 Acts Post-Transcriptionally During Infection to Regulate Gene Expression”Virology186:74-86 (1992).
Soneoka, et al., “A Transient Three-Plasmid Expression System for the Production of High Titer Retroviral Vectors”Nucl. Acids Res. 23(4):628-633 (1995).
Yeh, et al., “Efficient Dual Transcomplementation of Adenovirus E1 and E4 Regions from a 293-Derived Cell Line Expressing a Minimal E4 Functional Unit”J. Virol. 70(1):559 (1996).
Yla-Herttuala, et al., “Cardiovascular Gene Therapy”Lancet355:213-222 (Jan. 2000).
Santiago, et al. “Induction of the Transcriptional Repressor Yin Yang-1 by Vascular Cell Injury”,The Journal of Biological Chemistry, 2001.

Affiliated with

Also associated with

Rating

Inhibiting cellular proliferation by expressing yin yang-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibiting cellular proliferation by expressing yin yang-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibiting cellular proliferation by expressing yin yang-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4099400